Natixis Advisors
ARIA

Natixis Advisors’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Natixis Advisors’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-14,787
Closed -$272K – 1193
2013
Q3 		$272K Buy
14,787
+3,783
+34% +$73.5K 0.01% 999
2013
Q2 		$192K Buy
+11,004
New +$195K ﹤0.01% 1026

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Natixis Advisors's ARIA Position: Q4 2013 in Review

Natixis Advisors sold out of Ariad Pharmaceuticals Inc (ARIA) in Q4 2013, closing a stake of 14,787 shares — an estimated $272K sold.

Natixis Advisors first reported a position in ARIA in Q2 2013 and held it in 2 quarters. The position peaked at $272K in Q3 2013. 166 funds tracked by Wall St. Rank hold ARIA as of Q4 2013.

  • Natixis Advisors reported no remaining Ariad Pharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Natixis Advisors sold 14,787 Ariad Pharmaceuticals Inc shares in Q4 2013, an estimated $272K.
  • Natixis Advisors first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 2 quarters.
  • Natixis Advisors's Ariad Pharmaceuticals Inc position peaked at $272K in Q3 2013.
  • 166 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q4 2013.

Based on Natixis Advisors's 13F filing for Q4 2013, filed 12 Feb 2014.